Robert Deans

Robert Deans

Company: Bluerock Therapeutics

Job title: Chief Technology Officer


Robert Deans is CTO at BlueRock Therapeutics, a biotechnology company creating innovative cell therapeutics by harnessing gene editing tools and pluripotent stem cell biology.  Prior to BlueRock, he was CSO at Rubius Therapeutics, a red cell therapeutics platform company.  Dr Deans was previously EVP at Athersys, Inc, an adult stem cell therapeutics company now in late stage clinical development, and prior to that VP of Research at Osiris, Inc, developing the Prochymal MSC based product.  Dr Deans was also experienced in hematopoietic gene therapy while Director at the Immunotherapy Division of Baxter Healthcare.



Engineering Next Generation Macrophage from iPSC 2:30 pm

• Enable allogeneic practice by gene editing the immune locus • Control macrophage polarity using synthetic biology and logic circuits • Understand how iPSC manufacturing transforms treatment paradigms from a transplant model to biologicsRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.